Gene therapy of gliomas: Receptor and transcriptional targeting

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3223-3231

  Spear, Matthew A ^a,b,c  

^a UCSD MEDICAL CENTER   (United States)

^b VCSO Med Center Radiation Oncology   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenovirus; Amplicon; Brain tumor; CNS malignancies; Gene therapy; Glioblastoma; Glioma; HSV 1; Phage display; Promoter; Retrovirus; Targeting; Transcriptional regulation; Vector

Indexed keywords

EXPRESSION VECTOR; GENE THERAPY; GLIOMA; METHODOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; RECOMBINANT DNA TECHNOLOGY; REVIEW; TARGET CELL;

GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; RECEPTORS, GROWTH FACTOR; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC;

EID: 0031761897     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Gutin PH, Prados MD, Phillips TL, Wara WM, Larson DA, Leibel SA, Sneed PK, Levin VA, Weaver KA, Silver P et al: External irradiation followed by an intersittial high activity iodine-125 implant "boost" in the initial tratment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21: 601-606,1991.
2. Gottschalk S, Cristiano R, Smith L and Woo SL: Folate receptor-mediated DNA delivery and expression in vitro. Gene Ther 1: 185-191, 1994.
3. Cristiano R and Roth J: Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 3: 4-10, 1996.
4. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT and Birnstiel ML: Coupling of adenovirus to transferrin-polylysine DNA complexes greatly engances reptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci 89: 6099-6103, 1992.
5. Coll JL, Wagner E, Combaret V, Metchler K, Amstutz H, Iacono-Di-Cacito I, Simon N and Favrot MC: In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer. Gene Ther 4: 156-161, 1997.
6. Gao L, Wagner E, Cotten M, Agarwal S, Harris C, Romer M, Miller L, Hu PC and Curiel D: Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes. Hum Gene Ther 4: 17-24, 1993.
7. Cheng PW: Receptor Ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum Gene Ther 7: 275-282, 1996.
8. Huwyler J, Wu D and Pardridge WM: Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93: 14164-14169, 1996.
9. Spear MA, Li C, Weissleder R, Putney S, Pechan P and Breakefield XO: Ox26 Monoclonal Antibody Targets HSV-1 Vector to Transferrin Receptor-Bearing Cells. Proc Am Assoc Cancer Res 38: 343(abstr 2302), 1997.
10. Albritton LM, Tseng L, Scadden D and Cunningham JM: A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and congers susceptibility t virus infection. Cell 57: 659-66, 1989.
11. Miller DG, Edwards RH and Miller AD: Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 91: 78-82, 1994.
12. Kasahara NK, Dozy AM and Kan YW: Tissue specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1375, 1994.
13. Han X, Kasahara N and Kan YW: Ligand-directed retroviral targeting of human breast cancer cells. Proc natl Acad Sci 92: 9747-9751, 1995.
14. Chu TH, Marinez I, Sheay WC and Dornberg R: Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Therapy 1: 292-299, 1994.
15. Chu TH and Dornburg R: Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 71: 720-725, 1997.
16. Hong SS, Karayan L, Tournier J, Curiel DT and Boulanger PA: Adenovirus type 5 fiber knob bind t MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 16: 2294-2306, 1997.
17. Bergelson JM, Cunningham JA, Drouguett G, Kurt-Jones EA, Kritghivas A, Hong JS, Horwitz MS, Crowell RI and Finberg RW: Isolation of a common receptor for coxsackie D viruses and adenovirus 2 and 5. Science 275: 1320-1323, 1977.
18. Michael SI, Hong JS, Curiel DT and Engler JA: Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 2: 660-668, 1995.
19. Wickharn TJ, Tzeng E, Shears L L II, Roelvink P W, Li Y, Lee G M, Brough D E, Lizonova A and Kovesdi I: Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virolo 71: 8221-8229, 1997.
20. Harold BC, WuDunn D, Soltys N and Spear PG: Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J Virol 65: 1090-1098, 1991.
21. Trybala E, Bergstrom T, Svennerholm B, Jeansson S, Glorioso JC, Olofsson S: Localiztion of a functional sit on herpes simplex virus type I glycoprotein C invovled in binding to cell surface heparan sulphate. J Gen Virol 75: 743-52, 1994.
22. Cai W, Gu B and Person S: Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J Virol 62: 2596-2604, 1988.
23. Spear et al., unpublished.
24. Gray KD and Roth MJ: Mutational analysis of the envelope gene of Moloney murine leukemia virus. J Virol 67: 3489-3496, 1993.
25. Schnierle BS, Moritz D, Jeschke M and Groner B: Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Therapy 3: 334-342, 1996.
26. Herrnanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B and Nister M: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 54: 45, 1992.
27. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil MG, Wiestler OD, et al: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77: 295-301, 1992.
28. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ et al: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148, 1995.
29. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL and Wong AJ: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55: 5536-5539, 1995.
30. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I and Kreitman RJ: Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 56: 5631-5637, 1996.
31. Kreitman RJ, Puri RK, Pastan I: Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor bearing carcinoma. Cancer Res 55: 3357-3363, 1995.
32. Higuchi M, Ohnishi T, Arita N, Hiraga S and Hayakawa T: Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol 85: 481-487, 1993.
33. Ventimiglia JB, Wikstrand CJ, Ostrowdki LE, Bourdon MA, Lightner VA and Bigner DD: Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36: 41-55, 1992.
34. 131I-labled anti-tenascin monoclonal antibody 81 C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49: 2807-2813, 1989.
35. 131I-radiolabled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14F(ab')2-a preliminary report. J Neurooncol 24: 109-122, 1995.
36. Gladson CL and Cheresh DA: Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 88: 1924-1932, 1991.
37. Gladson CL, Wilcox JN, Sanders L, Gillespie GY and Cheresh DA: Cerebral microenvironment ingluences expression of the vitronectin gene in astrocytic tumors. J Cell Science 108: 947-956, 1995.
38. Jaworski DM, Kelly GM, Piepmeier JM and Hockfield S: BEHAB (Brain Enriched Hyaluronan Binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 56: 2293-2298, 1996.
39. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP and Jain RK: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55: 3752-3756, 1995.
40. Rainov NG, Zimmer C, Chase M, Krarnm CM, Chiocca EA, Weissleder R and Breakefield XO: Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 6: 1543-1552, 1995.
41. Fishman JB, Rubin JB, Handrahan JV, Connor JR and Fine RE : Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neruosci Res 19: 299-304, 1987.
42. Urien S, Pinquier JL, Paquette B, Chaumet-Riffaud P, Kiechel JP and Tillement JP: Effect of the binding of isradipine and darodapine to different plama proteins and their transfer through the rat blood-brain barrier: drug binding to lipoproteyls does not limit the transfer of drug. J Pharmacol Exp Ther 242: 349-353, 1987.
43. Frieden PM: Receptor-mediated transport of peptides and proteins across the blood-brain barrier. The Blood-Brain Barrier. WM Pardridge (ed). Raven Press, Ltd.: New York, pp. 229-247, 1993.
44. Yanase T, Tamura M, Fujita K, Kodarna S and Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53: 2566-2570, 1993.
45. Plate KH, Breier G, Weich HA, Mennel HD and Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1995.
46. Hatva E, Kaipainen A, Mentula P, Jaaskelainen J, Paetau A, Haltia M and Alitalo K: Expression of endothelial cell-specific receptor tyrosine kinases growth factors in human brain tumors. Am J Path 146: 368-378, 1995.
47. Martell LA, Agrawal A, Ross DA and Muraszko KM: Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53: 1348-1353, 1993.
48. Ito T, Recht L, Salimi A, Brill AB, Raso V and Griffin T: Delivery of antitransferrin receptor MABS into human glioma xenografts: autoradiographic studies. Proc Annu Meet Am Assoc Cancer Res 32: A1608, 1991.
49. Parmley SF and Smith GP: Antibody-selectable filamentous fd phage vectors: Affinity purification of target genes. Gene 73: 305-318, 1989.
50. Ladner RC and Guterman SK: PCT patent application W090/02809, 1990.
51. Scott JK and Smith GP: Searching for peptide ligands with an epitope library. Science 249: 386-390, 1990.
52. Pasqualini R and Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature 380: 364-366, 1996.
53. Van Ewijk W, de Kruif J, Germeraad WT, Berendes P, Ropke C, Platenburg PP and Logtenberg T: Subtractive isolation of phage-displayed single chain antibodies to thymic stromal cells by using intact thymic fragments. Proc Natl Acad Sci USA 94: 3903-3908, 1997.
54. O'Neil KT and Hoess R: Phage display: protein engineering by directed evolution. Cur Opinion Struct Biol 5: 443-449, 1995.
55. Pasqualini R, Koivunen E and Roushlahti E: αv integrins as receptors for tumor targeting by cirulating ligands. Nat Biotech 15: 542-546, 1997.
56. Okuyama T, Huber RM, Bowling W, Pearline R, Kennedy SC, Plye MW, Ponder KP: Liver directed gene therapy: a retroviral vector with a complette LTR and the ApoE enhancer-α1-antitrypsin promoter dramatically increases expressio of human α1-antitrypsin in vivo. Hum Gene Ther 7: 637-645, 1996.
57. Paulus W, Baur I, Boyce FM, Breakefield XO and Reeves SA: Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 70: 62-67, 1996.
58. Ferrari G, Salvatori G, Rossi C, Cossu G and Mavilio F: A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther 6: 733-742, 1995.
59. Vile RG and Hart IR: In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53: 962-967, 1993.
60. Hensen JW: Regulation of the glial specific JC virus early promoter by the transcription factor Sp 1. J Biol Chem 269: 1046-1050, 1994.
61. Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA and Breakefield XO: A novel "piggyback" packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther 7: 2003-2013, 1996.
62. Miyao Y, Shimizu K, Moriuchi S, Yamada M, Nakahira K, Nakajima K, Nakao J, Kuriyama S, Tusjii T, Mikoshiba K, Hayakawa T and Ikenaka K: Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. J Neurosci Res 36: 472-479, 1993.
63. Besnard F, Brenner M, Nakatani Y, Chao R, Purohit HJ and Freese E: Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J Biol Chem 266: 18877-18883, 1991.
64. Brenner M, Kisseberth WC, Su Y, Besnard F and Messing A: GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 14: 1030-1037, 1994.
65. Zimmerman L, Parr B, Lendahl U, Cunningharn M, McKay R, Gavin B, Mann J, Vassileva G and McMahon A: Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. Neuron 12: 11-24, 1994.
66. Ding D, Toth M, Zhou Y, Parks C, Hoffman BJ and Shenk T: Glial cell specific expression of the serotonin 2 receptor gene: selective reactivation of a represeed promoter. Brain Res Mol Brain Res 20: 181-191, 1993.
67. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG and Fine HA: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Med 3: 1145-1149, 1997.
68. Harris J, Hurst H, Lemoinen and Sikora K: Transcriptional targeting and tumor-specific gene therapy for cancer. Gene Ther 1: S14, 1994.
69. Ozaki K, Yoshida T, Ide H, Saito I, Ikeda Y, Sugimura T and Terada M: Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. Hum Gene Ther 7: 1483-1490, 1996.
70. Hallahan D, Kataoka Y, Kuchibhotla J, Virudachalam S and Weischelbaum R: Tissue specific promoters improve the localization of radiation-inducible gene expression. Int J Radiat Oncol Biol Phys 36 (Suppl): 226 (abstr 136), 1996.
71. Datta R, Rubin E, Suchatme V, Qureshi S, Halahan D, Weichselbaum RR and Kufe DW: Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 89: 10149-10153, 1992.
72. Boothman DA, Lee IW and Sahijdak WM: Isolation of an x-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of x-ray-responsive elements for gene therapy. Rad Res 138: S68-71, 1994.
73. Kondratyev AD, Chung KN and Jung MO: Identification and characterization of a radiation-inducible glycosylated human early-response gene. Cancer Res 56: 1498-1502, 1996.
74. Sherman ML, Datta R, Hallahan DE, Weichselbaum RR and Kufe DW: Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci USA 87: 5663-5666, 1996.
75. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R and Kufe D: Ionizing radiation induces expression and binding activity of the nuclear factor kappa b. J Clin Invest 88: 691-695, 1991.
76. Ishihara H, Tsuneoka K, Dimchev AB and Shikita M: Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 133: 321-326, 1993.
77. Peter RU, Beetz A, Ried C, Michel G, van Beuningen D and Ruzicka T: Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res 136: 65-70, 1993.
78. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A Helman S, Kufe DW and Weischelbaum RR: Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 8: 786-791, 1995.
79. Stevens CW, Zeng M and Cemiglia GJ: Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther 7: 1727-1734, 1996.
80. Herrlinger U, Breakefield XO, Jacoby D, Fraefael C, Spear MA, Schuback D, Pechan P, Smith F and Johnston KM: Transduction of human glioma cells by HSV/AAV hybrid amplicon vectors is increased by ionizing radiation. Proc Am Assoc Cancer Res 38: 343 (abs 85), 1997.
81. Kim JH, Kim SH, Kolzsvary BS, Brown SL, Kim OB and Freytag SO: Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cell in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 33: 861-868, 1995.
82. Kim JH, Kim SH, Brown SL and Freytag SO: Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells tranduced with HSVtk gene. Cancer Res 54: 6053-6056, 1994.
83. Weischelbaum RR, Hallahan DE, Becket MA, Hauceri HJ, Lee H, Sukhatme VP and Kufe DW: Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 54: 4266-4269, 1994.
84. Rogulski KR, Zhang K, Kolozsvary, Kim JH and Freytag SO: Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 3: 2081-2088, 1997.
85. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W and Bujanrd H: Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769,1995.
86. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992.
87. Rivera VM, Clackson T, Sridaran N, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F, Holt DA and Gilman M: A humanized system for pharmacologic control of gene expression Nat Med 2: 1028-1032, 1996.
88. Braselmann S, Graninger P and Busslinger M: A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc Natl Acad Sci 90: 1657-1661, 1993.
89. Whelan J and Miller N: Generation of estrogen receptor mutants with altered ligand specificity for use in establishing a regulatable gene expression system. J Steroid Biochem Mol Biol 58: 3-12, 1996.
90. Wang Y, Tsai SY and O'Malley BW: A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 91: 8180-8184, 1994.
91. Lu B and Federoff HJ: Herpes simplex virus type I amplicon vectors with glucocorticoid-inducible gene expression. Hum Gene Ther 6: 419-428, 1995.
92. Fishman JB, Rubin JB, Handrahan JV, Connor JR and Fine RE: Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neruosci Res 19: 299-304, 1987.
93. Moolten FL: Tumor chemosensitivity conferred by inserted thymidine kinase genes: a paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986.
94. Goldstein DJ and Veller SK: Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62: 196-205, 1988.
95. Martuza RL, Malick A, Markert JM, Ruffner KL and Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856, 1991.
96. Jones N and Shenk T: An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci USA 76: 3665-3669, 1979.
97. Yew PR, Kao CC and Berk AJ: Dissection of functional domains in the adenovirus 2 early 1B 55Kpolypeptide by suppressor-linker insertional mutagenesis. Virol 179: 795-805, 1990.
98. Dixon RAF and Schaffer PA: Fine-structure mapping and functional analysis of temperature-sensative mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. J Virol 36: 189-203, 1980.
99. Sacks WR, Green CC, Aschmann DA and Schffer PA: Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J Virol 55: 796-805, 1985.
100. Spear MA, Sakamoto KM, Herrlinger U, Pechan P and Breakefield XO: Function ofthe EGR-1/TIS8 Radiation-Inducible Promoter in a Minimal HSV-1 Amplicon System. Int J Rad Oncology, Biology and Physics 39 (suppl): 250 (abs 2020), 1997.
101. Miyatake S, Iyer A, Martuza RL and Rabkin SD: Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 71: 5124-5130, 1997.
102. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW and Henderson DR: Prostate attenuated replication competant adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57: 2559-2563, 1997.
103. Arbuthnot P, Bralet MP, Thamassin H, Danan JL, Brechot C and Ferry N: Hepatoma cell-specific expression of a retrovirallly transferred gene is achieved by alphfetoprotein but no insulir-like growth factor II regulatory sequences. Hepatology 22: 1788-1796, 1995.
104. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116: 205-213, 1994.
105. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S and Kisismoto T: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell-type specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54: 5258-5261, 1994.
106. Shimizu K: Selective gene therapy of malignant gliomas using brain-specific promoters: its efficacy and basic investigation. Nippon Rinsho (Japanese J Clin Med) 52: 3053-3058, 1996.
107. Arteaga CL and Holt JT: Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res 56: 1098-1103, 1996.
108. Chen L, Chen D, Manome Y, Dong Y, Fine HA and Kufe DW: Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 96: 2775-2782, 1995.
109. Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G and Chung LWK: Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res 56: 4614-4619, 1996.
110. Pang S, Dannul J, Kaboo R, Xie Y, Tso C, Michel K, deKemion JB and Belldegrun AS: Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 57: 495-499, 1996.
111. Lee CH, Liu M, Sie KL and Lee MS: Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-a and topoisomerase Iia in prostate cancer. Anticncer Res 16: 1805-1812, 1996.
112. Massuda ES, Dunphy EJ, Redman RA, Schreiber JJ, Nauta LE, Barr FG, Maxwell IH and Cripe TP: Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells. Proc Natl Acad Sci USA 94: 14701-1470, 1997.
113. Smith MJ, Rousculp MD, Goldsmith KT, Curiel DT and Garver RK: Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum Gene Ther 5: 29-35, 1994.
114. Vile RG, Diaz RM, Miller N, Mitchell S, Russell SJ: Tissue-specific gene expression form Mo-MLV retrovirual vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214: 307-313, 1995.
115. Myers RL, Ray SK, Eldridge R, Chotani MA and Chiu IM: Functional characterization of the brain-specific FGF-1 promoter, FGF-1.B. J Biol Chem 270: 8257-8266.
116. Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H and Hatanaka M: Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76: 792-798, 1992.
117. Ueki K, Ono Y, Henson IW, Efird JT, von Deimling A and Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153, 1996.
118. Matsuoka S, Yamaguchi M, Hiyashi Y and Matsukage A: Nucleotide seqence and promoter-specific effect of a negative regulatory region located upstrem of the mouse proliferating cell nuclear antigen gene. Eur J Biochem 218: 173-181, 1993.
119. Schiffer D, Cavalla P, Dutto A, Borsotti L: Cell proliferation and invasion in malignant gliomas. Anticancer Res 17: 61-69, 1997.
120. Thatikunta P, Sawaya BE, Denisova L, Cole C, Yusibova G, Johnson EM, Khalili K and Amini S: Identification of a cellular protein that binds to Tat-responsive element of TGF beta-I promoter in glial cells. J Cell Biochem 67: 466-477, 1997.
121. Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W and Heffner RR Jr: Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropath Exp Neurol 56: 435-439, 1997.
122. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991.
123. Weindel K, Moringlane JR, Marme D, Weich HA: Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurg 35: 439-448, 1994.